

**Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin)
Recombinant Antibody
Catalog # APR10183****Specification****Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	P20273
Reactivity	Rat, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	151.97 KDa

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Additional Information**Target/Specificity**
Siglec-2 / CD22**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
MMAE**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Protein Information****Name** CD22 {ECO:0000303|PubMed:1691828, ECO:0000312|HGNC:HGNC:1643}**Function**
Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed:34330755, PubMed:8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the

negative regulation of BCR signaling (PubMed:8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:20516366).

Cellular Location

Cell membrane; Single-pass type I membrane protein

Tissue Location


B-lymphocytes.

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) - Images



Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) is more than 95%, determined by SEC-HPLC.



Immobilized human Siglec 2 / CD22, His Tag at 2 µg/mL can bind Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) $\square$ EC50=0.008851 µg/mL